Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Have Novo Nordisk shares got further to go? This investment bank has its say
08:53am, Monday, 15'th Jan 2024
Stifel has identified Novo Nordisk (NYSE:NVO), Merck KGaA, and Sandoz as top picks in the European pharmaceutical sector for the first quarter of 2024, according to its recent research note. Novo Nord
Move Over, Novo Nordisk -- This Is the Pharmaceutical Company I am Most Bullish On in 2024
06:45am, Sunday, 14'th Jan 2024
Eli Lilly manufactures medication similar to Ozempic called Mounjaro. Zepbound, which has the same active ingredient as Mounjaro, was recently approved for treating obesity.
After Surging 53% in 2023, This Pharmaceutical Stock Might Be About to Crash. Here's Why I'm Probably Wrong
10:30am, Saturday, 13'th Jan 2024
Novo Nordisk makes the popular weight treatments Ozempic, Wegovy, Saxenda, and Rybelsus. Success of each of these medications has fueled unprecedented growth for the Danish company.
3 Unstoppable Stocks to Buy in 2024
07:48am, Saturday, 13'th Jan 2024
Eli Lilly is growing by leaps and Zepbounds. Novo Nordisk is just getting warmed up after delivering a 53% gain last year.
Why Novo Nordisk Stock Soared 53% in 2023 (Hint: It Wasn't Just Ozempic)
05:48am, Saturday, 13'th Jan 2024
Ozempic was a big factor behind Novo Nordisk's success last year, but not the biggest growth driver. The drugmaker had a lot of good news that boosted its stock price in 2023.
Novo Nordisk resumes shipments of Wegovy 1.7 mg dose in US
06:59pm, Friday, 12'th Jan 2024
Novo Nordisk said on Friday it resumed shipments of weight loss drug Wegovy in the 1.7 milligram dose in early January, following a short-term stock-out in the U.S. in mid-December last year.
FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts
09:02am, Friday, 12'th Jan 2024
The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.
Novo Nordisk: Enjoying The Tailwinds Of A Growing Market
12:25am, Friday, 12'th Jan 2024
Novo Nordisk is the market leader of the fast-growing obesity care industry, which is expected to grow above 20% CAGR until 2030. The company raised three times its guidance during 2023, driven by a 4
Bullish Continuation in '24? 3 Market Areas to Watch
02:17pm, Wednesday, 10'th Jan 2024
Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.
What is Wegovy worth to your employer? Companies wrestle with obesity drugs' costs, long-term value.
09:00am, Wednesday, 10'th Jan 2024
Amid mounting evidence of obesity drugs' longer-term health benefits, thorny questions persist about their value to employers.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
07:38pm, Tuesday, 09'th Jan 2024
In the most recent trading session, Novo Nordisk (NVO) closed at $106.95, indicating a +0.52% shift from the previous trading day.
Novo Nordisk A/S (NVO) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript
02:36pm, Tuesday, 09'th Jan 2024
Novo Nordisk A/S (NVO) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript
Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal
12:47pm, Tuesday, 09'th Jan 2024
Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.
3 Simple Tricks That Every Investor Should Use (but Most Don't)
10:15am, Tuesday, 09'th Jan 2024
There's no rule that mandates betting on only one company in a sector. It's valuable to learn about the top people involved in a business.
Wall Street Raises The Bar For These Four Stocks In 2024
05:30pm, Monday, 08'th Jan 2024
Nvidia is one of four stocks with rising profit estimates for 2024. Others are MercadoLibre, Deckers Outdoor and Novo Nordisk.
